1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 triall;Oaknin;Lancet,2023
3. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240);Tewari;Lancet,2017
4. First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826;Monk;J Clin Oncol,2023
5. The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer;Aghbash;Oncol Res,2023